Rein Therapeutics ALRN Stock
Rein Therapeutics Price Chart
Rein Therapeutics ALRN Financial and Trading Overview
| Rein Therapeutics stock price | 2.11 USD |
| Previous Close | 1.85 USD |
| Open | 1.9 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 900 |
| Day's Range | 1.77 - 1.94 USD |
| 52 Week Range | 1.12 - 9 USD |
| Volume | 25.24K USD |
| Avg. Volume | 26.59K USD |
| Market Cap | 8.33M USD |
| Beta (5Y Monthly) | 2.010563 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40 USD |
ALRN Valuation Measures
| Enterprise Value | -8392500 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.25472224 |
| PEG Ratio (5 yr expected) | -0.13 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.5835189 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.364 |
Trading Information
Rein Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.010563 |
| 52-Week Change | -78.062% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9 USD |
| 52 Week Low | 1.12 USD |
| 50-Day Moving Average | 1.51 USD |
| 200-Day Moving Average | 2.6 USD |
ALRN Share Statistics
| Avg. Volume (3 month) | 26.59K USD |
| Avg. Daily Volume (10-Days) | 28.11K USD |
| Shares Outstanding | 4.54M |
| Float | 3.06M |
| Short Ratio | 1.47 |
| % Held by Insiders | 9.02% |
| % Held by Institutions | 29.93% |
| Shares Short | 28.1K |
| Short % of Float | 0.76% |
| Short % of Shares Outstanding | 0.61% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -50.54% |
| Return on Equity (ttm) | -94.025% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -23044000 USD |
| Net Income Avi to Common (ttm) | -23686000 USD |
| Diluted EPS (ttm) | -5.28 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.72M USD |
| Total Cash Per Share (mrq) | 3.68 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.931 |
| Book Value Per Share (mrq) | 3.143 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -21726000 USD |
| Levered Free Cash Flow (ttm) | -12150375 USD |
Profile of Rein Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 285 Summer Street |
| ZIP | 02210 |
| Phone | 617 995 0900 |
| Website | https://www.aileronrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 6 |
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Q&A For Rein Therapeutics Stock
What is a current ALRN stock price?
Rein Therapeutics ALRN stock price today per share is 2.11 USD.
How to purchase Rein Therapeutics stock?
You can buy ALRN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rein Therapeutics?
The stock symbol or ticker of Rein Therapeutics is ALRN.
Which industry does the Rein Therapeutics company belong to?
The Rein Therapeutics industry is Biotechnology.
How many shares does Rein Therapeutics have in circulation?
The max supply of Rein Therapeutics shares is 21.67M.
What is Rein Therapeutics Price to Earnings Ratio (PE Ratio)?
Rein Therapeutics PE Ratio is 0.00000000 now.
What was Rein Therapeutics earnings per share over the trailing 12 months (TTM)?
Rein Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Rein Therapeutics company belong to?
The Rein Therapeutics sector is Healthcare.
Rein Therapeutics ALRN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Capital Market Composite RCMP | 96.46 USD — |
-4.76
|
— — | 95.94 USD — | 97.68 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}